CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 2,800 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 2,800 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total value of $147,840.00. Following the completion of the transaction, the general counsel directly owned 87,815 shares in the company, valued at approximately $4,636,632. This represents a 3.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP traded down $0.59 during midday trading on Friday, reaching $48.28. The company’s stock had a trading volume of 1,272,153 shares, compared to its average volume of 1,980,759. The business’s fifty day simple moving average is $54.20 and its 200-day simple moving average is $57.28. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The company has a market capitalization of $4.63 billion, a P/E ratio of -7.38 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The firm’s quarterly revenue was down 97.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.01) EPS. On average, analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mcguire Capital Advisors Inc. acquired a new position in shares of CRISPR Therapeutics in the 4th quarter valued at $25,000. Ramirez Asset Management Inc. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $26,000. Rothschild Investment LLC grew its stake in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. increased its holdings in CRISPR Therapeutics by 196.9% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after purchasing an additional 382 shares during the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new position in CRISPR Therapeutics in the second quarter valued at about $33,000. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY‑2025 commercial progress: CRSP reported $116M in FY‑25 revenue driven by CASGEVY, with $54M in Q4, supporting longer‑term revenue potential. CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth
• Positive Sentiment: Institutional buying noted: Coverage flagged that ARK Invest bought CRSP shares, signaling institutional interest that can provide buying support despite volatility. CRISPR Therapeutics (CRSP) Stock Plunges 10% as Cathie Wood’s ARK Invest Scoops Up Shares
• Positive Sentiment: Analyst tweaks modestly constructive: Brookline Capital’s updates include small upward revisions to near‑term FY2026/FY2027 EPS (less negative), which slightly improves the near‑term earnings outlook (changes are minor).
• Neutral Sentiment: Retail/investor attention rose: Zacks/Yahoo flagged CRSP among most‑searched stocks, indicating higher retail interest that can amplify moves but is not a directional signal by itself. Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
• Neutral Sentiment: Short‑interest reporting appears noisy: recent short‑interest entries in feeds show inconsistent/zero values (likely data artifacts) — not a clear signal on positioning.
• Negative Sentiment: Convertible note offering: CRISPR priced an upsized $550M convertible senior notes offering due 2031. Markets often react negatively to large convertible financings because of potential dilution and share supply; that offering coincided with sharp intraday weakness. CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
• Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales of shares (~9,798 and 2,800 shares, respectively), which can be perceived as a near‑term negative signal for sentiment. Insider Sales by CEO Samarth Kulkarni
• Negative Sentiment: Recent sharp intraday declines: media coverage noted multi‑percent drops in recent sessions after the financing news, amplifying volatility and likely contributing to continued selling pressure. CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. TD Cowen increased their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Needham & Company LLC lifted their target price on CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, February 13th. Evercore reaffirmed an “outperform” rating and set a $74.00 price target on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Finally, Citigroup reiterated a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and a consensus price target of $64.24.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.